According to HSAs June 2025 approval notice, Tirzepatide KwikPen was approved in Singapore for weight management, including weight loss and weight maintenance, in adults with an initial BMI of at least 30, or BMI 27 to under 30 with at least one weight-related comorbid condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes
It runs the whole gamut, from people not losing enough weight to having too many symptoms, to being thrilled
These predispositions may help provide context for your provider about why you respond a certain way to semaglutide, potentially guiding levothyroxine adjustment timing and dose magnitude as weight loss progresses
Build Habits That Stick The key to lasting change
This supplement is derived via a fermentation process to ensure a highly stable formula with high levels of bioavailability
These are: 1